Client news
Entera prices $275 million PIPE, Israel’s largest biotech private placement
Congratulations to Entera Bio (NASDAQ: ENTX) and CEO Miranda Toledano on announcing a landmark $275 million oversubscribed private placement led by BVF Partners.
Based on publicly disclosed financings, this is believed to be Israel’s largest-ever biotech PIPE, with participation from Longitude Capital, Vivo Capital, TCGX, Venrock Healthcare Capital Partners, RA Capital Management, Perceptive Advisors, Logos Capital, Catalio Capital Management and others.
Entera is advancing EB613, an oral PTH(1-34) peptide tablet designed to become the first oral anabolic treatment for osteoporosis. Proceeds are expected to fund operations into 2030 and fully support the Phase 3 program.
Leerink Partners acted as lead placement agent, with Evercore ISI, Guggenheim Securities, Cantor, LifeSci Capital and Canaccord Genuity as co-placement agents. Greenberg Traurig and Herzog Fox Neeman acted as counsel to Entera.
At Arx we are proud to have supported Entera through two transformative financing rounds, FDA milestones, earnings, and day-to-day capital markets work.